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Staphylococcus aureus in the nose is a risk factor for endogenous staphylococcal infection. UK guide-
lines recommend the use of mupirocin for nasal decolonization in certain groups of patients colonized
with methicillin-resistant S. aureus (MRSA). Mupirocin is effective at removing S. aureus from the nose
over a few weeks, but relapses are common within several months. There are only a few prospective
randomized clinical trials that have been completed with sufﬁcient patients, but those that have been
reported suggest that clearance of S. aureus from the nose is beneﬁcial in some patient groups for the
reduction in the incidence of nosocomial infections. There is no convincing evidence that mupirocin
treatment reduces the incidence of surgical site infection. New antibiotics are needed to decolonize
the nose because bacterial resistance to mupirocin is rising, and so it will become less effective.
Furthermore, a more bactericidal antibiotic than mupirocin is needed, on the grounds that it might
reduce the relapse rate, and so clear the patient of MRSA for a longer period of time than mupirocin.
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Nasal decolonization of methicillin-susceptible Staphylococcus
aureus (MSSA) and methicillin-resistant S. aureus (MRSA) is
currently used in some countries for speciﬁc patient groups. For
example, in the UK it is recommended
1 that carriers of MRSA,
who are receiving prophylaxis for an operation, should undergo
nasal decolonization with mupirocin. Mupirocin is effective at
removing S. aureus from the nose over a few weeks, but nasal
relapses are common within several months.
2 There are few pro-
spective randomized clinical trials (RCTs) with sufﬁcient
patients to achieve statistical signiﬁcance that have been com-
pleted in this ﬁeld.
3 Taken together, these trials suggest that
clearance of S. aureus from the nose is beneﬁcial in some
patient groups.
4 This paper describes the risks, beneﬁts and
importance of patient selection in the use of mupirocin to deco-
lonize the anterior nares.
S. aureus strains
MSSA lives on the skin of humans as a commensal. In devel-
oped countries 30%
5–7 of the general adult population are
colonized, although the data range from as low as 15%
8 up to
100%, in speciﬁc populations, such as those with MSSA skin
infections.
9 Nasal colonization (stable colonization is deﬁned as
S. aureus in the nose detected from nasal swabs taken several
days apart) with strains such as MRSA is much lower, at 1%
of the total population,
10 and is more frequent in certain sub-
groups of patients such as frequently hospitalized people, those
of advancing age, patients on dialysis, AIDS patients and
diabetics.
1,11
Colonization with MRSA has been shown to increase the
risk of infection with MRSA both immediately after coloni-
zation
12 and in long-term carriers, of whom 23% develop
MRSA infections in the year following the identiﬁcation of
their carriage status.
13 Patients who have had contact with
healthcare facilities such as hospitals may be colonized in
the nose with healthcare-associated (HA) MRSA. A different
set of MRSA strains affects patients who have not had
recent contact with healthcare units, and these strains are
called community-associated (CA) MRSA. HA-MRSA
usually causes diseases such as bacteraemia and infective
endocarditis that tend to be more multiresistant. In contrast
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skin and soft tissue infections and other infections such as
the serious necrotizing pneumonia.
11 It is currently less mul-
tiresistant than HA-MRSA and is usually susceptible to com-
monly used antibiotics such as tetracyclines, but is more
virulent, e.g. it invades tissue more readily, partly as a result
of some strains that carry the Panton-Valentine leucocidin
toxin gene.
14
Methicillin resistance of MRSA is determined by carriage of
the mecA gene that encodes a variant of the penicillin binding
protein 2A, which has a low afﬁnity for b-lactam antibiotics.
The mecA gene is found on the staphylococcal cassette chromo-
some (SCC). Different strains of MRSA have SSCmec numbered
I to VI. SCCmec types I to III are typically found in
HA-MRSA,
15 while CA-MRSA characteristically carries the two
smallest SCCmec, types IV
16 and V.
17 CA-MRSA grows faster
in vitro than HA-MRSA, indicating a greater genetic ﬁtness in
the absence of the selection pressures from the widespread use
of antimicrobials that shaped the genetic background of
HA-MRSA strains.
14 CA-MRSA is thought to be currently using
some of the more ‘successful’ genetic lineages from MSSA such
as ST30 (Oceania clone) or ST8 (USA 300 clone).
15 Around the
world CA-MRSA is presenting with changing resistance pro-
ﬁles
14 and outbreaks outside hospitals have been reported from
close communities such as prisons,
18 military barracks,
19 rafting
guide companies
20 and American football teams.
21 This evol-
ution towards communicability and toxicity is likely to present
new challenges for infection control.
Morbidity, mortality and economic impact of
S. aureus disease
It has been estimated
22 that S. aureus in the USA in 2005 was
responsible for 478000 nosocomial infections, 58% from
MRSA, that progressed to cause 10800 deaths overall with 5500
from MRSA. Although MRSA has been associated with higher
infection
23 rates than MSSA, it is thought that at least some of
this effect is due to differences in the severity of co-morbid
illness.
24 The cost to health services of controlling and treating
S. aureus infections is high with one study in the USA
suggesting $9.7 billion in 2001.
25 The impact of S. aureus
infections on society as a whole is harder to quantify.
S. aureus transmission and adhesion
The ways in which S. aureus is transmitted and the mechanisms
behind its survival in the nasal environment are important factors
in colonization. It is likely that transmission from one individual
to another is mediated by hand-to-nose contact, indicated by the
association of hand carriage,
26 and of habitual nose-picking,
27 to
nasal carriage. Aerial transmission
28 is an alternative route and
may be particularly important in instances of colonized patients
with allergies who tend to release higher S. aureus loads.
29,30
Having reached the anterior nares, the next step towards success-
ful colonization is for the bacteria to effectively adhere to the
nasal epithelial cells. Interactions between humans and S. aureus
determine the nature of the nasal carriage and are inﬂuenced by
the genotypes of both the host and microbe.
31
Competition between staphylococci for colonization
in the anterior nares
The ‘ecological niche’ of the anterior nares has a ﬁnite area that
can be colonized and there is competition between different gen-
otypes for this space. One study
32 observed nasal colonization
with MSSA in 17% of patients and 8% with MRSA.
However, only 0.6% were co-colonized with both and so the
investigators concluded that, whilst different organisms can
compete for the same niche, in this case MSSA has greater
ﬁtness, which suggests that it may prevent colonization by
MRSA. The ﬁtness advantage of MSSA over MRSA can be
accounted for by the added resistance mechanism(s) of MRSA
that incur viability and competitiveness costs.
33,34
Does nasal colonization with S. aureus matter?
Nasal colonization as a risk factor for S. aureus disease
S. aureus (including MRSA) colonization of the nose is an
endemic risk factor for infectious diseases such as bacteraemia
and skin and soft tissue infections in many patient populations,
6
e.g. the general hospital population,
35 patients undergoing
general,
5 thoracic
36 and orthopaedic
37 surgery, patients being
treated in intensive care units (ICUs),
38 non-surgical patients
(including those on haemodialysis),
39 continuous ambulatory
peritoneal dialysis (CAPD) patients,
40 HIV-positive patients
41
and liver transplant patients.
42
It seems that most S. aureus disease is caused by the patient’s
own bacteria. The rates of S. aureus autoinfection, where the
S. aureus strain detected from the wound matches that swabbed
from the nose, are high both in observational studies and in
RCTs. Autoinfection rates tend to lie between 76% and
86%.
3,43–45 The density at which the anterior nares are colo-
nized may be a further risk factor; a 3-fold increase in surgical
site infections (SSIs) has been reported in surgical patients with
high concentrations of nasal S. aureus.
37 These associations do
not necessitate causality and both could conceivably be pro-
duced by a third party such as immunological changes inﬂuen-
cing bacterial activity. Crucially though, evidence that nasal
S. aureus decolonization leads to a decreased incidence of
S. aureus infection in certain cases, is an important indication
that nasal colonization is implicated in autoinfection.
3,4
Mupirocin removes MRSA and MSSA from the nose
Mupirocin is established as the best topical antimicrobial avail-
able for Gram-positive bacteria
1,46 and has been applied to the
task of nasal decolonization since the 1980s to target nasal
S. aureus carriage on the grounds that S. aureus carriage is a
risk factor for S. aureus disease.
47 It is a relatively potent deco-
lonizing agent; immediately after completion of nasal mupirocin
treatment, 81.5% to 100% of patients are successfully decolo-
nized compared with spontaneous or vehicle-mediated decoloni-
zation rates of 0% to 46%.
3,48–50 Under everyday working
conditions, poor patient compliance may reduce the effect
further. For example, in one case, mupirocin only decolonized
6% of patients.
50
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Mupirocin acts on isoleucyl tRNA synthetase to inhibit protein
synthesis.
51 It is this enzyme that is the focal point of resistance.
Emergence of bacterial resistance to mupirocin, in many cases,
is rising.
52,53 Interestingly though, signiﬁcant increases in resist-
ance to mupirocin have been reported in one hospital with only
light mupirocin usage,
54 while regular usage in another was not
sufﬁcient to increase the mupirocin resistance.
55 There are two
phenotypes of mupirocin-resistant S. aureus, ‘low-level’ and
‘high-level’ (LL-MR and HL-MR, respectively), and both are
able to cause treatment failure.
56 The working deﬁnition of
LL-MR is a mupirocin MIC of 8–256 mg/L and the working
deﬁnition of HL-MR is a mupirocin MIC of 512 mg/L. The
LL-MR genotype is a mutation of the chromosomal gene ileS-2
(mupA), which encodes a resistant version of isoleucyl tRNA
synthetase, while HL-MR’s genotype is a plasmid-transferrable
alternative version of the same gene.
34 An estimated 6.6% of
patients who carry S. aureus are colonized with multiple
strains,
57 so presenting an opportunity for horizontal gene trans-
fer both for developing new strains
58 and perpetuating the resist-
ance genes themselves. The plasmid can be incorporated into
other species such as Staphylococcus epidermidis
59 to act as a
potential reservoir.
60 The mutation behind LL-MR is readily
induced by exposure to mupirocin in vitro.
61 This resilience of
S. aureus resistance mechanisms means that mupirocin resist-
ance is unlikely to be eradicated on the removal, or restriction,
of mupirocin use, particularly as LL-MR mutations are not
associated with a signiﬁcant ﬁtness burden over mupirocin-
susceptible S. aureus.
34
In one study
56 decolonization was achieved on day 3 after
mupirocin treatment in 78.5% of mupirocin-susceptible MRSA,
80% of LL-MR MRSA and 27.7% of HL-MR MRSA. At
4 weeks, 91% of the mupirocin-susceptible MRSA group were
still culture-negative, whilst only 25% of both the LL-MR and
HL-MR MRSA groups were culture-negative. This 75% LL-MR
MRSA persistence suggests even low-level resistance is sufﬁ-
cient to lead to treatment failure. If mupirocin-susceptible
MRSA and LL-MR MRSA can be considered to have similar
exogenous infection rates, then this result indicates that LL-MR
MRSA recolonization is due to endogenous relapse rather than
exogenous recolonization. The endogenous relapse may be
attributable to latent bacterial sub-populations that may be difﬁ-
cult to detect by culture methods.
62
Does nasal decolonization beneﬁt the patient?
There are only a few
3,45,48 prospective RCTs that have been
completed with sufﬁcient patients, assessing the beneﬁts of
nasal decolonization, but those that have been reported suggest
that the clearance of S. aureus from the nose is beneﬁcial in
some patient groups.
Surgery
In clean elective surgery in developed countries, the baseline
rate for SSI is 1%–5% of which S. aureus causes 30%–50%.
63
A recent study,
48 with strong methodology and the only prospec-
tive RCT assessing SSIs performed with blinding during the
data analysis, found that, despite clearing 81.5% of nasal
S. aureus, no signiﬁcant effect of mupirocin on the outcome of
SSIs caused by S. aureus occurred (total S. aureus infections:
3.8% mupirocin, 3.2% placebo; P¼1.00, CI ¼ 0.32–4.69).
Another large RCT, by Perl et al.,
3 concluded that mupirocin
did not signiﬁcantly reduce S. aureus SSIs, but that it did signiﬁ-
cantly reduce the total number of nosocomial S. aureus infec-
tions among the S. aureus carriers. A third study
45 found that
mupirocin did not signiﬁcantly reduce the S. aureus SSI rate
even though there were 5-fold fewer endogenous S. aureus SSIs
in the mupirocin group than in the control group.
One shared issue
48 that runs through these trials is that
mupirocin has a minimal effect in reducing infections in uncolo-
nized individuals. This dilutes the power of these studies and
could contribute to the non-signiﬁcant results found by both Perl
et al.
3 and Kalmeijer et al.,
45 but not for those found in the later
2006 study
48 (which used data only from colonized patients).
Another factor that may have led to the lower than average
infection rates in these trials, hence further power dilution, is
simply that participation in studies induces healthcare staff to
maintain higher standards of hygiene and care, similar to the
effect observed by French et al.
64 in 1989, and may have led the
investigators in the smaller trials to underestimate the number of
subjects needed to contract disease.
48 Nonetheless, the results
from the two 2002 trials can be combined to increase the power
of the trends that were shown to near statistical signiﬁcance
(P¼0.06, pooled OR¼0.58, 95% CI¼0.33–1.02). A recent
meta-analysis
4 suggested that these three trials, together with
one other,
65 gave pooled results that, although still failing to
substantiate nasal S. aureus decolonization with mupirocin as a
means of reducing S. aureus SSIs, did generate sufﬁcient signiﬁ-
cance to support mupirocin as an effective means to reduce all
postoperative S. aureus infections, including SSI. In this study,
4
3.6% of S. aureus infectious diseases occurred in the mupirocin-
treated group versus 6.7% in the controls (RR¼0.55, 95%
CI¼0.34–0.89, P¼0.02).
Very large numbers of patients would be needed to conﬁrm
intranasal mupirocin’s efﬁcacy in reducing SSI with statistical
signiﬁcance. It is estimated that 14000 patients
66 with a base-
line SSI rate of 5% would be needed to demonstrate a 20%
reduction in the SSI rate. It is not likely that this study will be
undertaken, because of the large investment that would be
required in relation to the size of the market.
ICUs
MRSA constitutes .64% of S. aureus isolates in US ICUs.
67
One study reported that 8% of admissions to ICUs carried
MRSA in the nose and the acquisition of MRSA carriage
whilst in the ICU was 10%.
68 The high prevalence of MRSA
in ICUs presents a threat to the rest of the hospital population
when patients are discharged from the ICU into other hospital
wards with their accompanying MRSA
69 and, therefore, nasal
decolonization with mupirocin may be useful in ICUs. In a
prospective, randomized double-blinded study
70 it was
suggested that the inclusion of mupirocin, intranasally and in
an oral paste, signiﬁcantly reduced MRSA lung infections (7
of 104 cases in the placebo group versus 1 of 119 cases in
the treatment group; P,0.05). Further clinical trials suggest
that mupirocin is useful for reducing endogenous MRSA
infections in ICUs.
71
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Studies looking at the long-term efﬁcacy of mupirocin that have
focused on nasal decolonization of S. aureus, including MRSA,
have shown that initial clearance over several weeks is effective
but that recolonization after 3 months is high.
2,72 It has been
established that signiﬁcant increases in resistance to mupirocin
can occur after repeated or extended courses of mupirocin
73 and,
in order to maximize the potential therapeutic beneﬁts of mupir-
ocin, it is recommended this such usage is avoided.
1 In dialysis
patients, mupirocin treatment regimens have been described as
effectively reducing infection although also increasing the preva-
lence of resistance to mupirocin.
74 However, it is possible to
simply reduce the prevalence of S. aureus colonization without
altogether eliminating carriage so minimizing the potential for
induction of resistance. In care homes, 3 months after effective
decolonization, recolonization rates are 39%
75 to 24%.
76 Of
these recolonizations, 86% were relapses rather than exogenous
recolonization.
75 Another study, in a gastroenterology unit, indi-
cated that mupirocin signiﬁcantly reduced nasal MRSA coloni-
zation and infection rates over 55 months using a single course
of mupirocin.
77 In a study on healthy hospital staff, intranasal
mupirocin affected a near complete decolonization; 6 months
after treatment nasal colonization was 56% (the placebo group
maintained 72% colonization) while 1 year after treatment nasal
carriage was 53% (the placebo group maintained 76% coloniza-
tion; RR¼0.70, 95% CI¼0.48–1.02, P¼0.056).
2
What are the alternatives?
New antibiotics are needed to decolonize the nose due to the
rise in bacterial resistance to mupirocin and its subsequent
reduction in effectiveness. Additionally, a more bactericidal anti-
biotic than mupirocin is needed on the grounds that it might
reduce the relapse rate, so clearing the patient of S. aureus for a
longer period of time than mupirocin and reducing the associ-
ated risks of infection. We have not included other agents that
are currently used in some countries, such as neomycin, chlor-
hexidene or fusidic acid, because, in a limited number of clinical
trials, these agents have been shown to be either less effective
than mupirocin or are not licensed for nasal decolonization of
staphylococci.
78,79
Drugs coming on to the market
A number of drugs, at varying stages of development, which
might be more effective for nasal S. aureus decolonization than
mupirocin, are on their way to the market. These come from a
range of sources, large as well as small pharmaceutical compa-
nies (in the case of Replidyne, with inputs from both). The
drugs have a diversity of mechanisms.
Replidyne’s REP8839 has a similar mechanism of action to
mupirocin, acting on the methionyl tRNA synthetase (MetRS)
rather than isoleucyl tRNA synthetase to inhibit protein syn-
thesis. MetRS is thought to be a particularly good target as it
takes the ﬁrst step in translating the methionine required for both
the initiation and elongation of peptide chains in vitro. REP8839
is active against Gram-positive skin bacteria such as S. aureus
and Streptococcus pyogenes. The drug completed Phase I clini-
cal trials in 2007,
80 but its development has since slowed.
Novabay’s N,N-dichloro-2,2-dimethyltaurine is a stabilized ana-
logue of the endogenous N-chlorotaurine oxidants synthesized
by activated granulocytes.
81 Also known as NVC-422, the
oxidant ﬁnished, in May 2008, Phase IIa clinical trials as a deco-
lonization spray for nasal S. aureus, clearing 88% of colonized
subjects.
82 Destiny Pharma is adapting the principles of photo-
dynamic therapy to antimicrobials with its lead compound
XF-73. XF-73 is a photosensitive porphyrin derivative that
causes a light-dependent disruption of membrane integrity
83 and
has shown potent clearance of MRSA on ex vivo porcine skin
samples.
84
Phico Therapeutics
85 is developing a bacteriophage approach
to eliminate S. aureus and, in particular, MRSA. Its lead pro-
gramme, SASPject
TM, has completed pre-clinical trials for nasal
decolonization. Its in vitro activity against different S. aureus
strains, bar vancomycin-intermediate S. aureus/vancomycin-
resistant S. aureus,i s.3 log reduction in viable counts after
6 h. The modiﬁed S. aureus-speciﬁc bacteriophage PTSA1.2/A
delivers the complementary a/b-type small acid-soluble spore
protein gene from Bacillus megaterium, which is then translated
into its protein that ﬂips the bacterial DNA A-B resulting in bac-
terial cell death. The SASPject
TM application is focused and
conﬁned by the removal of the holin gene from the phage to
prevent budding and so viral propagation.
Helperby Therapeutics
86 has developed the compound HT61,
which showed a bactericidal effect against MSSA and MRSA in
the nose in a Phase IIa clinical trial. HT61 is active against
persistent bacteria that are not killed by antibiotics such as
mupirocin.
NICE report
The UK’s National Institute of Clinical Excellence (NICE) pub-
lished a report
87 on 22 October 2008 on SSIs, which states:
‘There is evidence that nasal decontamination with mupirocin or
chlorhexidine administered to all patients undergoing surgery
does not affect the overall rate of SSI. There is evidence that
nasal decontamination with mupirocin given to S. aureus car-
riers undergoing surgery does not reduce either the incidence of
S. aureus SSI or the incidence of all-cause SSI.’
NICE does not recommend the routine use of topical antimi-
crobial agents for nasal decontamination aimed at eliminating
S. aureus to reduce the risk of SSIs.
We agree with the recommendations of the NICE report, but
emphasize that there is evidence that mupirocin treatment
reduces the incidence of S. aureus nosocomial infections in
S. aureus carriers. The report does not comment on the use of
mupirocin for the prevention of nosocomial infections.
Accordingly, we suggest that usage of mupirocin should concen-
trate on the prevention of nosocomial infections in carriers. The
reason for the failure of mupirocin to prevent SSIs is unknown,
but may be due to lack of power in the clinical trials
55 or to a
lack of efﬁcacy of mupirocin in this patient sub-group.
Conclusions
The evidence suggests that intranasal mupirocin is a useful tool
for reducing S. aureus autoinfection when patients are at high-
risk in the short-term, such as in an ICU. Whilst it reduces the
Review
12risk of nosocomial infection, it has not been shown to reduce the
risk of SSIs. It is also useful for reducing symptomless spread in
hospitals. When patients are at risk of colonization and infection
from MRSA, such as those patients on long-term haemodialysis,
CAPD and in care homes, its utility is limited by the need to
avoid the induction of resistance to it. The rising emergence of
S. aureus resistance to mupirocin will eventually reach a point at
which its beneﬁts are restricted to the extent that its use is no
longer economically viable. It is vital that at least some of
the new antimicrobial therapies under development reach the
market, both to provide a more effective solution to the issue of
long-term nasal colonization and to replace mupirocin when it
becomes redundant.
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